CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-09-12 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 900,686 |
| 2023-09-12 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −25,000 | $8.43 | $211K | 875,686 |
| 2023-09-12 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 1,372,635 | ||
| 2023-09-06 | Gibson Christopher Chief Executive Officer | Exercise or conversion | +31,250 | $2.48 | $78K | 905,056 |
| 2023-09-06 | Gibson Christopher Chief Executive Officer | Sale | −33,765 | $8.78 | $297K | 871,291 |
| 2023-09-06 | Gibson Christopher Chief Executive Officer | Conversion | +4,000 | 4,000 | ||
| 2023-09-06 | Gibson Christopher Chief Executive Officer | Sale | −4,000 | $8.83 | $35K | 0 |
| 2023-09-06 | Gibson Christopher Chief Executive Officer | Conversion | +20,000 | 20,000 | ||
| 2023-09-06 | Gibson Christopher Chief Executive Officer | Sale | −20,000 | $8.83 | $177K | 0 |
| 2023-09-06 | Gibson Christopher Chief Executive Officer | Conversion | +1,000 | 1,000 | ||
| 2023-09-06 | Gibson Christopher Chief Executive Officer | Sale | −1,000 | $8.84 | $9K | 0 |
| 2023-09-06 | Gibson Christopher Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −31,250 | 500,000 | ||
| 2023-09-06 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −4,000 | 523,000 | ||
| 2023-09-06 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −20,000 | 448,000 | ||
| 2023-09-06 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −1,000 | 120,875 | ||
| 2023-09-05 | Borgeson Blake Director | Sale | −8,885 | $8.79 | $78K | 7,451,845 |
| 2023-08-24 | Larson Tina Marriott President and COO | Exercise or conversion 10b5-1 | +3,000 | $1.06 | $3K | 421,782 |
| 2023-08-24 | Larson Tina Marriott President and COO | Sale 10b5-1 | −2,937 | $8.64 | $25K | 418,845 |
| 2023-08-24 | Larson Tina Marriott President and COO | Sale 10b5-1 | −63 | $9.45 | $596 | 418,782 |
| 2023-08-24 | Larson Tina Marriott President and COO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −3,000 | 529,000 |
Page 32 of 41 · 805 trades